{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T02:09:00Z","timestamp":1787796540265,"version":"build-2784847793"},"reference-count":19,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca PLC","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journal-of-hepatology.eu","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Hepatology"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.jhep.2026.06.025","type":"journal-article","created":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T00:26:54Z","timestamp":1783297614000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Durvalumab with gemcitabine-based chemotherapy regimens in advanced biliary tract cancer: Primary results from the phase IIIb TOURMALINE study"],"prefix":"10.1016","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1663-9901","authenticated-orcid":false,"given":"Do-Youn","family":"Oh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4050-2086","authenticated-orcid":false,"given":"Masafumi","family":"Ikeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teresa","family":"Macarulla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aiwu Ruth","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joon Oh","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masayuki","family":"Kitano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9310-1075","authenticated-orcid":false,"given":"Guido","family":"Giordano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyu-pyo","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Wirth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Tai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3919-4135","authenticated-orcid":false,"given":"Mohamed","family":"Bouattour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6919-1536","authenticated-orcid":false,"given":"Tiziana","family":"Pressiani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4970-5189","authenticated-orcid":false,"given":"Farshid","family":"Dayyani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Lamarca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ugochinyere","family":"Emeribe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanne","family":"Radke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-1877-8666","authenticated-orcid":false,"given":"Boris","family":"Baur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arndt","family":"Vogel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jhep.2026.06.025_bib1","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/S0140-6736(21)00153-7","article-title":"Biliary tract cancer","volume":"397","author":"Valle","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.jhep.2026.06.025_bib2","series-title":"FDA approves durvalumab for locally advanced or metastatic biliary tract cancer","year":"2022"},{"key":"10.1016\/j.jhep.2026.06.025_bib3","doi-asserted-by":"crossref","first-page":"305","DOI":"10.3390\/cancers17020305","article-title":"Treatment patterns and outcomes in patients with advanced biliary tract cancers treated with gemcitabine-based chemotherapy: a retrospective study","volume":"17","author":"Dayyani","year":"2025","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.jhep.2026.06.025_bib4","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2200015","article-title":"Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer","volume":"1","author":"Oh","year":"2022","journal-title":"NEJM Evid"},{"key":"10.1016\/j.jhep.2026.06.025_bib5","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1016\/j.jhep.2025.05.003","article-title":"Durvalumab plus chemotherapy in advanced biliary tract cancer: 3-year overall survival update from the phase III TOPAZ-1 study","volume":"83","author":"Oh","year":"2025","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2026.06.025_bib6","series-title":"Imfinzi: summary of product characteristics","year":"2026"},{"key":"10.1016\/j.jhep.2026.06.025_bib7","series-title":"Imfinzi (durvalumab): highlights of prescribing information","year":"2026"},{"key":"10.1016\/j.jhep.2026.06.025_bib8","series-title":"Imfinzi plus Imjudo approved in Japan for advanced liver and non-small cell lung cancers, and Imfinzi approved for unresectable biliary tract and liver cancers","year":"2022"},{"key":"10.1016\/j.jhep.2026.06.025_bib9","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1016\/S0140-6736(23)00727-4","article-title":"Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"401","author":"Kelley","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.jhep.2026.06.025_bib10","series-title":"NCCN clinical practice guidelines in Oncology (NCCN Guidelines\u00ae). Biliary tract cancers. Version 1.2026","year":"2026"},{"key":"10.1016\/j.jhep.2026.06.025_bib11","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.annonc.2022.10.506","article-title":"Biliary tract cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"34","author":"Vogel","year":"2023","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jhep.2026.06.025_bib12","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2024.103647","article-title":"Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with biliary tract cancer","volume":"9","author":"Chen","year":"2024","journal-title":"ESMO Open"},{"key":"10.1016\/j.jhep.2026.06.025_bib13","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejps.2024.106939","article-title":"Advances in understanding cisplatin-induced toxicity: molecular mechanisms and protective strategies","volume":"203","author":"Elmorsy","year":"2024","journal-title":"Eur J Pharm Sci"},{"key":"10.1016\/j.jhep.2026.06.025_bib14","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1056\/NEJMoa0908721","article-title":"Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer","volume":"362","author":"Valle","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2026.06.025_bib15","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2025.115373","article-title":"Safety of accelerated infusion of nivolumab and pembrolizumab","volume":"220","author":"van Rijssen","year":"2025","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.jhep.2026.06.025_bib16","article-title":"Durvalumab plus chemotherapy for advanced biliary tract cancer: a post hoc analysis of the TOPAZ-1 randomized clinical trial","volume":"Jul 9","author":"Oh","year":"2026","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.jhep.2026.06.025_bib17","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1200\/OP-25-00275","article-title":"Beyond infusion: real-world insights into infusion-related reactions in monoclonal antibody therapy","volume":"22","author":"Smolders","year":"2026","journal-title":"JCO Oncol Pract"},{"key":"10.1016\/j.jhep.2026.06.025_bib18","doi-asserted-by":"crossref","DOI":"10.1016\/j.annonc.2022.07.080","article-title":"52MO A randomized phase II trial of durvalumab and tremelIMUmab with gemcitabine or gemcitabine and cisplatin compared to gemcitabine and cisplatin in treatment-naive patients with CHolangio- and gallbladdEr Carcinoma (IMMUCHEC)","volume":"33","author":"Vogel","year":"2022","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jhep.2026.06.025_bib19","doi-asserted-by":"crossref","DOI":"10.1016\/j.annonc.2024.08.054","article-title":"45P Durvalumab (D) plus gemcitabine-based (gem-based) chemotherapy as first-line therapy for Chinese patients (pts) with advanced biliary tract cancers (aBTC): a phase IIIb, single arm, open-label, multi-center study (TopDouble)","volume":"35","author":"Sun","year":"2024","journal-title":"Ann Oncol"}],"container-title":["Journal of Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827826026589?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827826026589?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,22]],"date-time":"2026-08-22T04:38:08Z","timestamp":1787373488000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168827826026589"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":19,"alternative-id":["S0168827826026589"],"URL":"https:\/\/doi.org\/10.1016\/j.jhep.2026.06.025","relation":{},"ISSN":["0168-8278"],"issn-type":[{"value":"0168-8278","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Durvalumab with gemcitabine-based chemotherapy regimens in advanced biliary tract cancer: Primary results from the phase IIIb TOURMALINE study","name":"articletitle","label":"Article Title"},{"value":"Journal of Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jhep.2026.06.025","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V. on behalf of European Association for the Study of the Liver.","name":"copyright","label":"Copyright"}]}}